Pipeline & Assets

Drug Candidates

Drug Candidate

For the Treatment of

Moderate to Severe Eczema

Pre-Clinical Stage ✅
Clinical Stage ✅
NDA Submitted ☑️
NDA Approved ☑️

Turn’s flagship formula has shown potent efficacy against staph, as well as a lack of cytotoxicity, sensitization, and irritation in humans. The opportunity to safely address a root cause of eczema is now.

Drug Candidate

For the Treatment of

Onycomychosis

Pre-Clinical Stage ✅
Clinical Stage ✅
NDA Submitted ☑️
NDA Approved ☑️

Topical antifungals are widely considered ineffective per CDC (6-16%), yet still generate billions of dollars in revenue annually.

Preliminary research conducted by key opinion leading physicians suggests our flagship formula’s potential efficacy is ~70-85% (n=100) for the treatment of onychomycosis.

Drug Candidate

Indicated for

MRSA-Pathogen Burden Reduction

Pre-Clinical Stage ✅
Clinical Stage ✅
NDA Submitted ☑️
NDA Approved ☑️

Nasal decolonization is a common part of protocols intended to reduce the likelihood of systemic infections caused by MRSA.

Our formulation is 99.9% effective against MRSA, biocompatible, and meets eligibility requirements for FDA’s QIDP program.

Medical Devices

Medical Device

Antimicrobial Oil Emulsion Dressing

XEAL

Pre-Clinical Stage ✅
Clinical Stage ✅
FDA Market Approval (510k) ✅

XEAL Antimicrobial Oil Emulsion Dressing is impregnated with petrolatum-based Hexagen Antimicrobial.

Medical Device

Antimicrobial Collagen Powder

FLEX AM

Exclusively Licensed to MIMEDX

Medical Device

Management of Atopic Dermatitis

AtopX

Pre-Clinical Stage ✅
Clinical Stage ✅
FDA Market Approval (510k) ✅

The same formula composition as our original, flagship Hexagen formula indicated for the management of symptoms related to atopic, irritant, and radiation dermatitis.

Lead candidate for drug approval for the treatment of moderate to severe eczema. Drug approval will facilitate patient access through traditional retail pharmacy channels.